VistaGen Therapeutics (NASDAQ:VTGN) Releases Earnings Results, Beats Expectations By $0.14 EPS

VistaGen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings results on Friday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.14, FiscalAI reports. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.50 million.

VistaGen Therapeutics Stock Performance

Shares of NASDAQ:VTGN traded up $0.00 during midday trading on Friday, reaching $0.18. 402,286 shares of the company’s stock traded hands, compared to its average volume of 4,567,498. VistaGen Therapeutics has a one year low of $0.16 and a one year high of $5.14. The stock has a 50 day moving average of $0.22 and a 200 day moving average of $0.42. The company has a market cap of $8.01 million, a price-to-earnings ratio of -0.11 and a beta of 0.49.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines. Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder. The company’s pipeline has also included PH80, an intranasal therapy investigated for migraine and other neurological conditions, and PH10, an intranasal neuroactive compound studied for depressive disorders.